New cell therapy for MS enters human safety testing
NCT ID NCT07008378
First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This early-stage study tests an experimental cell therapy called P-CD19CD20-ALLO1 in 60 adults with multiple sclerosis. The main goal is to see if it is safe and how the body handles it. Researchers will also measure how long the cells last and how they affect the immune system.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Multiple Sclerosis Comprehensive Care Center at Northwell Health
New York, New York, 10075, United States
-
Rutgers University- Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08901-1962, United States
-
UCI Sue & Bill Gross Stem Cell Research Center
Irvine, California, 92697, United States
-
UCSD Altman Clinical and Translational Research Institute
La Jolla, California, 92037-1337, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110-1010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?